Charles Piercy, Jenny Harris, Kenza Sackho, Paola Campagnolo, Diogo Barardo, Ben Creagh-Brown, Christian Heiss
{"title":"Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial.","authors":"Charles Piercy, Jenny Harris, Kenza Sackho, Paola Campagnolo, Diogo Barardo, Ben Creagh-Brown, Christian Heiss","doi":"10.1093/ehjopen/oeag157","DOIUrl":"10.1093/ehjopen/oeag157","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate 6-month effects of a multi-ingredient nutritional powder formulation targeting complementary pathways relevant to vascular ageing on endothelial function and other vascular ageing markers in apparently healthy adults.</p><p><strong>Methods and results: </strong>The <i>effects of a supplement to target ageing mechanisms on vascular function study</i> was a double-blind, randomized, controlled trial. Participants received a multi-ingredient nutritional powder formulation comprising vitamins/minerals, amino acids, and plant-derived bioactives, or control for 6 months. Vascular assessments were performed at baseline and after 6 months (with an acute post-dose assessment). The primary outcome was change in brachial artery flow-mediated dilation (FMD). Secondary outcomes included pulse wave velocity (PWV), peripheral and central blood pressure, augmentation index, lipid profile, and estimated 10-year cardiovascular risk (SCORE2/SCORE2-OP). Sixty-one participants (baseline SCORE2/SCORE2-OP 3.6 ± 2.9%) were randomized (33 actives; 28 controls); 43 completed both visits (24 vs. 19). Compared with control, the supplement improved endothelial function (ΔΔFMD at 6 months +2.9% [95% CI 2.1-3.8]) and reduced arterial stiffness (ΔΔPWV -1.18 m/s [95% CI -2.00 to -0.36]). Peripheral systolic blood pressure (SBP) decreased (ΔΔSBP -6.1 mmHg [95% CI -10.9 to -1.3]). Lipids were unchanged. Estimated 10-year cardiovascular risk decreased (ΔΔSCORE2/SCORE2-OP -0.45% [95% CI -0.86 to -0.03]).</p><p><strong>Conclusion: </strong>Daily intake of a multi-ingredient nutritional powder formulation was associated with sustained improvements in endothelial function, arterial stiffness, and systolic blood pressure, with a modest reduction in estimated 10-year cardiovascular risk primarily attributable to lower systolic blood pressure rather than lipid change.</p><p><strong>Registration: </strong>clinicaltrials.gov NCT06145087.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag157"},"PeriodicalIF":4.3,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13730552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emmanuel Androulakis, Hamish MacLachlan, Elena Cavarretta, Vassilios S Vassiliou, Dimitra Antonakaki, Rocco Friebel, Meskerem Kebede, Raghav Bhatia, Sabiha Gati, Gherardo Finocchiaro, Michael Papadakis, Silvia Castelletti, Flavio D'Ascenzi
{"title":"ECG interpretation in athletes by expert sports cardiologists and nonspecialist medical professionals across Europe: a survey from the European association of preventive cardiology.","authors":"Emmanuel Androulakis, Hamish MacLachlan, Elena Cavarretta, Vassilios S Vassiliou, Dimitra Antonakaki, Rocco Friebel, Meskerem Kebede, Raghav Bhatia, Sabiha Gati, Gherardo Finocchiaro, Michael Papadakis, Silvia Castelletti, Flavio D'Ascenzi","doi":"10.1093/ehjopen/oeag183","DOIUrl":"10.1093/ehjopen/oeag183","url":null,"abstract":"<p><strong>Aims: </strong>We aimed to evaluate the real-world use of contemporary international ECG interpretation criteria in athletes, and to compare practices, clinical decision-making, and perceived barriers between specialist and nonspecialist professionals across Europe.</p><p><strong>Methods and results: </strong>Two sets of structured questionnaires were developed and distributed to either sports cardiologists or nonspecialist professionals. Knowledge of international guidelines, experience in ECG interpretation, and confidence levels in clinical decision-making across various clinical scenarios were evaluated. An open-ended questionnaire was also developed to explore aspects of ECG interpretation, medicolegal issues, relevant legal frameworks across European countries, and personal thoughts on possible future revisions to the documents. The questionnaires were revised and edited by expert sports cardiologists, affiliated with EAPC. Data were analysed both quantitatively and qualitatively. A total of 242 participants across Europe were included; 66% were male and 57% worked in public hospitals. Nonspecialists demonstrated uncertainty in standard definitions, classification systems, and key applications of ECG criteria. These findings highlight variability in preparticipation screening (PPS) practices and areas of uncertainty in clinical decision-making, alongside concerns regarding access to specialist services. Notably, 25% of specialists favoured a flexible interpretative approach beyond current standard criteria. The majority supported the need for updated guidance and improved description of specific ECG indices, including ventricular ectopy (83%), QRS fragmentation (83%), and low-amplitude QRS complexes (78%), alongside recognition of the potential role of artificial intelligence-based models. Gaps in knowledge, training, and practice were identified, and both groups emphasized medicolegal and pathway challenges.</p><p><strong>Conclusion: </strong>This international survey provides a contemporary real-world overview of ECG interpretation and PPS practice in athletes across Europe and revealed substantial heterogeneity in access to services, training, interpretation uncertainty, referral pathways, and medico-legal frameworks.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag183"},"PeriodicalIF":4.3,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maria Concetta Pastore, Giordano Castellano, Giulia Elena Mandoli, Alessia Culcasi, Andrea Marchese, Alessio Pecere, Anita Di Renzo, Simona Pavoncelli, Mara Toscano, Carlotta Rodriguez, Laura Spaccaterra, Luna Cavigli, Flavio D'Ascenzi, Ciro Santoro, Michael Y Henein, Serafina Valente, Marta Focardi, Matteo Cameli
{"title":"Multimodality imaging for the detection of cardiotoxicity in cancer patients treated with immune checkpoint inhibitors.","authors":"Maria Concetta Pastore, Giordano Castellano, Giulia Elena Mandoli, Alessia Culcasi, Andrea Marchese, Alessio Pecere, Anita Di Renzo, Simona Pavoncelli, Mara Toscano, Carlotta Rodriguez, Laura Spaccaterra, Luna Cavigli, Flavio D'Ascenzi, Ciro Santoro, Michael Y Henein, Serafina Valente, Marta Focardi, Matteo Cameli","doi":"10.1093/ehjopen/oeag179","DOIUrl":"10.1093/ehjopen/oeag179","url":null,"abstract":"<p><strong>Aims: </strong>Immune checkpoint inhibitors (ICIs) may cause cardiotoxicity, mainly myocarditis, with potential life-threatening consequences. To date, large-scale prospective data on cardiac imaging after ICI are still lacking. Thus, our primary aim was to assess the diagnostic value of speckle tracking echocardiography (STE) for ICI-related cardiotoxicity according to current international recommendations, while our secondary aims were to assess the prognostic value of STE for adverse clinical outcome and evaluate the agreement between STE and CMR in patients with ICI-related myocarditis.</p><p><strong>Methods and results: </strong>In this prospective study, cancer patients referred for cardiologic evaluation before ICIs initiation were enrolled. Patients with known cardiac dysfunction (LV ejection fraction < 40%) were excluded. All patients underwent clinical, biohumoral and echocardiographic evaluation completed by STE at baseline and at ∼6 months after immunotherapy. Patients with suspected myocarditis underwent CMR. Then, over a longer follow up, the clinical events were registered: all-cause or cardiovascular death, acute myocarditis, acute heart failure, pulmonary embolisms, acute coronary syndromes, atrial or ventricular arrhythmias, extra-cardiac toxicity. We enrolled 122 patients (65 ± 14 years) referred for ICIs. Over 7 ± 6 months follow up, mean LV GLS showed a slight reduction after therapy with ICI (-20 ± 4% at baseline vs. -18 ± 7%), although remaining within the normal ranges. During 22 ± 17 months of follow up, 65 patients developed events. Among ICI-related myocarditis, 4 patients showed a significant reduction of GLS with a regional distribution similar to regional myocardial injury at CMR (97 ± 7% agreement), the fifth had a minimal involvement of the right ventricle, with normal LV GLS.</p><p><strong>Conclusion: </strong>Our results suggest that multimodality imaging combining different techniques may optimize the subclinical diagnosis of cardiotoxicity and the overall management of cancer patients undergoing ICIs.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag179"},"PeriodicalIF":4.3,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eva Bianconi, Antonella De Palma, Davide Perico, Silvia Bruno, Francesca Fumagalli, Enrico Nicolis, Eliana Rulli, Davide Ceresa, Ambra Costa, Chiara Vitale, Roberto Latini, Pier Luigi Mauri, Pietro Ameri
{"title":"Circulating extracellular vesicle-enriched fraction in heart failure with reduced ejection fraction and incident cancer.","authors":"Eva Bianconi, Antonella De Palma, Davide Perico, Silvia Bruno, Francesca Fumagalli, Enrico Nicolis, Eliana Rulli, Davide Ceresa, Ambra Costa, Chiara Vitale, Roberto Latini, Pier Luigi Mauri, Pietro Ameri","doi":"10.1093/ehjopen/oeag180","DOIUrl":"10.1093/ehjopen/oeag180","url":null,"abstract":"<p><strong>Aims: </strong>Previous studies found increased cancer incidence in patients with heart failure with reduced ejection fraction (HFrEF). We sought to explore the biological correlates of the association of HFrEF with cancer in humans.</p><p><strong>Methods and results: </strong>Among participants in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trial with HFrEF and available baseline plasma samples, we selected those who developed solid cancer (cases) and matched them with controls without cancer by age, sex, New York Heart Association class, and follow-up duration. We isolated the plasma extracellular vesicle (EV)-enriched fraction, in which EVs were confirmed by western blot for CD9, FLOTILLIN-1, ALIX, and TSG101, and by nanoparticle tracking analysis (mean particle diameter <200 nm). The protein content of EV preparations was characterized by nanoliquid chromatography-high=resolution tandem mass spectrometry. Of the 940 identified proteins, 148 were differentially expressed between EV preparations from cases (EVs-cases) and controls (EVs-controls) and were related to biological functions implicated in cancer growth, particularly apoptosis and spliceosome/transcriptome regulation. Next, we explored the effects of EVs-cases and EVs-controls in MCF7 breast cancer cells and ran confirmatory experiments with another two cell lines, HCT116 (colon) and A549 (lung). Apoptosis, as determined by caspase 3 cleavage, was blunted by EVs-cases in MCF7, but not in HCT116 and A549 cells. Screening qPCR identified <i>NR3C1</i>, encoding the glucocorticoid receptor, as a spliceosome/transcription modulator affected by EVs-cases. Targeted qPCR confirmed that it was reduced by EVs-cases in A549 cells.</p><p><strong>Conclusion: </strong>Circulating EV-enriched fractions from patients with HFrEF and incident cancer have a distinct proteomic signature and might modulate human cancer cell biology.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag180"},"PeriodicalIF":4.3,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonio Kösters, Nikita Ermolaev, Mahshid Eslami, Leonhard Lichtblau, Lisa Seilinger, Stefanie Pahr, Mariusz Grzeda, Roza Badr Eslam
{"title":"One-minute heart rate recovery and clinical outcomes in transthyretin cardiac amyloidosis: incremental model fit beyond conventional CPET indices.","authors":"Antonio Kösters, Nikita Ermolaev, Mahshid Eslami, Leonhard Lichtblau, Lisa Seilinger, Stefanie Pahr, Mariusz Grzeda, Roza Badr Eslam","doi":"10.1093/ehjopen/oeag181","DOIUrl":"10.1093/ehjopen/oeag181","url":null,"abstract":"<p><strong>Aims: </strong>To assess the association of 1-min heart rate recovery (HRR1) with clinical outcomes and its incremental contribution to model fit beyond peak VO<sub>2</sub> and ventilatory efficiency (VE/VCO<sub>2</sub> slope) in transthyretin cardiac amyloidosis (ATTR-CM).</p><p><strong>Methods and results: </strong>Consecutive adults with confirmed ATTR-CM undergoing symptom-limited cardiopulmonary exercise testing (CPET) were included in this single-centre observational study. During standardized active recovery at 24 W, HRR1 was defined as peak heart rate minus heart rate exactly 60 s after exercise. Cox proportional-hazards models evaluated all-cause mortality and the composite of mortality or first heart-failure hospitalization. Principal models adjusted for age, sex, peak VO<sub>2</sub> and VE/VCO<sub>2</sub> slope; NT-proBNP and National Amyloidosis Centre (NAC) stage were examined separately. Of 161 baseline patients, 11 with unverifiable heart-rate measurements were excluded, and exact HRR1 was available in 110. Mortality analysis included 105 patients with 33 deaths; composite-outcome analysis included 107 patients with 51 events. Median HRR1 was 15.5 bpm. In conventional CPET-adjusted models, each 10-bpm greater HRR1 was associated with lower hazards of mortality [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.44-0.95; <i>P</i> = 0.028] and the composite outcome (HR 0.74, 95% CI 0.57-0.97; <i>P</i> = 0.029). Adding HRR1 improved model fit (likelihood-ratio <i>P</i> = 0.017 and <i>P</i> = 0.021, respectively); apparent C-indices increased from 0.770 to 0.795 for mortality and from 0.695 to 0.699 for the composite outcome. Associations were non-significant after separate adjustment for NT-proBNP or NAC stage.</p><p><strong>Conclusion: </strong>HRR1 remained associated with outcomes after CPET adjustment and improved model fit. Discrimination gains were modest; value beyond biomarker staging was unproven.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag181"},"PeriodicalIF":4.3,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to: Complex all-comers and patients with diabetes and prediabetes treated with Xience Sierra everolimus-eluting stents: COASTLINE high-risk.","authors":"","doi":"10.1093/ehjopen/oeag178","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag178","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/ehjopen/oeaf140.].</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 5","pages":"oeag178"},"PeriodicalIF":4.3,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13689707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Grethe Albrektsen, Tom Wilsgaard, Ivar Heuch, Dag S Thelle, Maja-Lisa Løchen, Sameline Grimsgaard, Kaare H Bønaa
{"title":"Sex differences in the diabetes-related risk of incident myocardial infarction and relationship to established coronary heart disease risk factors: the Tromsø Study (1979-2016).","authors":"Grethe Albrektsen, Tom Wilsgaard, Ivar Heuch, Dag S Thelle, Maja-Lisa Løchen, Sameline Grimsgaard, Kaare H Bønaa","doi":"10.1093/ehjopen/oeag174","DOIUrl":"10.1093/ehjopen/oeag174","url":null,"abstract":"<p><strong>Aims: </strong>To examine whether the adverse effect of diabetes on the risk of incident myocardial infarction (MI) differs between sexes and assess to what extent established coronary heart disease (CHD) risk factors contribute to the elevated risk.</p><p><strong>Methods and results: </strong>Prospective study of 42 907 Tromsø Study participants (51.5% women) with 3942 incident MI (357 with diabetes) at ages 35-104 years. Relative risks [incidence rate ratio (IRR)] were estimated in Poisson regression analyses. Impact of CHD risk factors was quantified as a percentage change in the regression coefficient for diabetes. A contrast in risk of MI by diabetes status was seen from age 45 years in men and 55 years in women. Adjusted for age and birth cohort, the IRR was 2.26 in women and 1.84 in men (<i>P</i> = 0.12, test for interaction). In a mutually adjusted model, adjustment for the triglyceride-to-HDL-cholesterol ratio weakened the association with diabetes similarly in women (-19.0%) and men (-17.0%); systolic blood pressure had a larger impact in women (-10.3% vs. +2.2%), whereas smoking strengthened the association more in men (+23.1% vs. +7.1%). Body mass index had a minor impact. A larger joint impact of adjustment factors in women (-33.6% vs. -15.9%) narrowed the initial gender gap (adjusted IRR of 1.72 and 1.67, respectively). Adverse lipid levels and increasing systolic blood pressure emerged already during the pre-diabetic phase.</p><p><strong>Conclusion: </strong>Traditional CHD risk factors contributed substantially to the diabetes-related risk of incident MI. A larger joint impact of these factors in women reduced the initial observed sex difference in the adverse effect of diabetes.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag174"},"PeriodicalIF":4.3,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Björn Agvall, Anders Halling, Håkan Nilsson, Awais Ashfaq, Pia Johansson
{"title":"Comparing two distinct costing models for health economics of heart failure within a Swedish population-based cohort.","authors":"Björn Agvall, Anders Halling, Håkan Nilsson, Awais Ashfaq, Pia Johansson","doi":"10.1093/ehjopen/oeag172","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag172","url":null,"abstract":"<p><strong>Aims: </strong>To compare two healthcare costing models, Cost Per Patient and Patient Encounter Costing, in patients with heart failure, quantify differences in estimated healthcare costs, and identify factors associated with discrepancies between the models.</p><p><strong>Methods and results: </strong>A retrospective register study was conducted in Region Halland, southwest Sweden, including 3230 patients aged 40-90 years with heart failure diagnosed at least twice between 2013 and 2018 and alive during 2019. Healthcare utilization costs during 2019 were estimated using the Cost Per Patient and Patient Encounter Costing models. Linear regression analyses were used to identify factors associated with costs and differences between the models. The Cost Per Patient model estimated a mean annual cost of €10 341 compared with €9538 for the Patient Encounter Costing model. Hospital care accounted for 73% of total costs in both models. Although overall cost estimates were similar, differences in outpatient and primary care costs reached 22%. Higher costs in both models were associated with diabetes, elevated N-terminal pro B-type natriuretic peptide levels, and impaired kidney function. Differences between the models were primarily explained by primary care visits, inpatient care days, and N-terminal pro B-type natriuretic peptide levels. Sensitivity analyses using log-transformed costs yielded similar results.</p><p><strong>Conclusion: </strong>Both Cost Per Patient and Patient Encounter Costing methodologies were useful for estimating healthcare costs in heart failure. The models provide different perspectives on healthcare costs because they use different cost-allocation principles. These differences should be considered when selecting a costing methodology for healthcare evaluations.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 5","pages":"oeag172"},"PeriodicalIF":4.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13717912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149303209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eirinaios Tsiartas, Sokratis Oikonomou, Aristea Iordanidou, Athanasios Samaras, Andreas S Papazoglou, Dimitrios V Moysidis, Vassileios Vassilikos, Antonios Ziakas, Periklis Davlouros, Konstantinos Tsioufis, Dimitrios N Tziakas, Ioannis Zarifis, George Giannakoulas
{"title":"Beta-blockers after acute coronary syndrome: insights across the ejection fraction spectrum.","authors":"Eirinaios Tsiartas, Sokratis Oikonomou, Aristea Iordanidou, Athanasios Samaras, Andreas S Papazoglou, Dimitrios V Moysidis, Vassileios Vassilikos, Antonios Ziakas, Periklis Davlouros, Konstantinos Tsioufis, Dimitrios N Tziakas, Ioannis Zarifis, George Giannakoulas","doi":"10.1093/ehjopen/oeag175","DOIUrl":"10.1093/ehjopen/oeag175","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the association between beta-blocker (BB) prescription and long-term all-cause mortality after acute coronary syndrome (ACS), and to assess whether this varies across the left ventricular ejection fraction (LVEF) spectrum.</p><p><strong>Methods and results: </strong>We analysed ACS patients from the retrospective multicentre CardioMining study (NCT05176769). The primary analysis used inverse probability of treatment weighting (IPTW) and restricted mean survival time (RMST) derived from weighted Kaplan-Meier curves. RMST and survival differences were estimated at 1 and 5 years. A landmark analysis evaluated survival between years 1 and 5 among first-year survivors. Among 6049 ACS patients (age 66.8 ± 13.2 years; 74.9% male), 5107 (84.4%) were discharged on BBs. During a median 4.6-year follow-up, 1912 deaths (31.6%) occurred. Overall, the 1-year RMST difference associated with BBs was 6.3 days (95%CI 0.0 to 13.2), which attenuated further by 5 years (11.3 days, 95%CI -30.7 to 63.9). The largest 1-year RMST difference was observed among patients with LVEF ≤40% (18.8 days, 95%CI 1.1 to 37.4), whereas associations were smaller and non-significant among patients with LVEF 41-49% and LVEF ≥50%. At 5 years, confidence intervals crossed the null across all LVEF categories. Continuous LVEF analyses suggested greater short-term benefit at lower values, with progressive attenuation across the LVEF spectrum. Among 1-year survivors, no significant RMST differences were observed between years 1 and 5.</p><p><strong>Conclusion: </strong>Discharge BB prescription was not associated with a clear long-term survival advantage after ACS in this large real-world cohort. Apparent associations were strongest at lower LVEF values and attenuated during longer follow-up.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag175"},"PeriodicalIF":4.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13732307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}